Novel immunostimulants and their use in immunotherapy

A new family of iNKT activators with PEG fragments and functional reactive groups addresses the need for more efficient and targeted immunotherapy by enhancing cytokine release and tumor-specific activation of iNKT cells, overcoming limitations of existing activators like KRN7000.

JP7587583B2Active Publication Date: 2024-11-20UNIV DE NANTES +2
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022542249
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-01-10
Filing Date
2021-01-08
Publication Date
2024-11-20
Estimated Expiration
2041-01-08

AI Technical Summary

Technical Problem

There is a need for more efficient and targeted immunostimulants for immunotherapy, particularly for cancer treatment, with improved activation of iNKT cells and reduced side effects.

Method used

Development of a new family of iNKT activators, including compounds of formula (II) with PEG fragments and functional reactive groups, which can be coupled to carriers such as antibodies or nanoparticles, allowing targeted delivery and activation of iNKT cells without requiring classical antigen-presenting cells.

Benefits of technology

The new iNKT activators exhibit significantly higher potency in cytokine release compared to KRN7000, enabling selective tumor targeting and reduced side effects by activating iNKT cells directly on tumor cells, even those considered 'non-CD1d' cells, and enhancing immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587583000050
    Figure 0007587583000050
  • Figure 0007587583000051
    Figure 0007587583000051
  • Figure 0007587583000052
    Figure 0007587583000052
Patent Text Reader

Abstract

The present invention relates to a new family of iNKT activators, called 6"-O-PEGm-NHR-GalCer, which are potent analogs of KRN7000. These iNKT activators can be advantageously used in therapy to prevent and / or treat many diseases that require stimulation of an immune response, such as cancer, viral, bacterial, or parasitic diseases, autoimmune diseases, or inflammatory diseases, among others. The iNKT cell activators of the present invention can be coupled to biological carriers, such as therapeutic and / or targeting agents, or vectorized, for example, into nanoparticles, for specific delivery to target cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to immunostimulants and their use in immunotherapy. [Background technology]

[0002] iNKT (Invariant Natural Killer T) cells are a unique population of lymphocytes that can specifically recognize glycolipid antigens. These antigens need to be presented, for example, by antigen-presenting cells through the non-classical MHC-I (Major Histocompatibility Complex Class I) molecule, CD1d.

[0003] KRN7000 (also called α-GalCer or alpha-galactosylceramide) is the canonical ligand for iNKT cells. KRN7000 is actually a synthetic glycolipid derived from agelasphin 9b produced by the marine sponge Agelas mauritianus. In response to the binding of KRN7000 to iNKT cells, these cells rapidly release large amounts of cytokines that can initiate or amplify immune responses. KRN7000 has been shown to protect against LPS-induced shock in various in vivo models and to exhibit potent antitumor activity. KNR7000-pulsed DCs (dendritic cells) or KNR7000 loaded with CD1d receptors have therefore been investigated in clinical trials for the treatment of chronic Hepatitis B and C infections, as well as for cancer therapy (especially non-small cell carcinoma, lung cancer, metastatic cancer, liver cancer, breast cancer, neck skin cancer, prostate cancer and head cancer), melanoma and solid tumors (myelodysplastic syndromes, multiple myeloma), etc.

[0004] KRN7000 has the following formula (I):

[0005] [ka]

[0006] has. Several analogs of KNR7000 have been disclosed, including minor 6"-O-modified GalCer derivatives, but the latest series of analogs showed the same iNKT activation or a slight improvement in iNKT activation (30-40%) compared to the reference KRN7000, in some cases with a better Th1 bias. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, USA, 1985) Summary of the Invention [Problem to be solved by the invention]

[0008] There remains a need to provide new immunostimulants for use in immunotherapy, in particular for the prevention and / or treatment of cancer, which are preferably more efficient and / or preferably have better targeting therapeutic selectivity. [Means for solving the problem]

[0009] The present inventors have synthesized a new family of activators of human iNKT cells that are surprisingly found to be the most potent iNKT activators known to date, some of which are even more potent than the reference glycolipid KRN7000.

[0010] This new family of iNKT activators includes compounds of formula (II):

[0011] [ka]

[0012] [wherein X is a PEG fragment -[CH2-CH2-O] m- (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents H, -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1, or -CSOR1; R1 is an alkyl group, an aryl group, a heterocyclic group, a PEG fragment -[CH2-CH2-O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer of 1 to 24), R2 represents a functional reactive group allowing coupling to a carrier D, or represents LD (where L is a linker and D is a carrier)], or comprises or consists of it.

[0013] For example, the compound 6-PEG-NH-GalCer 2a of formula (IV):

[0014] [ka]

[0015] showed approximately 10% greater cytokine release from iNKT cells than the parent KRN7000. 3 2b of formula (V):

[0016] [ka]

[0017] is 10 4~5 It shows twice the efficacy.

[0018] Due to their potent biological activity, these iNKT activators disclosed herein are extremely useful, particularly in the context of immunotherapy for cancer and other diseases, such as bacterial infections, viral infections, parasitic diseases, or autoimmune diseases (e.g., type I diabetes or multiple sclerosis).

[0019] Furthermore, another advantage of the iNKT activators disclosed herein is their unexpected ability to activate iNKT using tumor cells, previously considered to be "non-CD1d cells," as presenting cells themselves, without the need for recruitment of standard APCs (antigen presenting cells), e.g., DCs (dendritic cells), macrophages, etc.

[0020] The iNKT activators disclosed herein include 6-Mal-PEG6GalCer 3a (derived from 6-PEG3-NHR-GalCer 2a of formula (IV)), which has the following formula (VII):

[0021] [ka]

[0022] has.

[0023] The iNKT activators of formula (VII) exhibit an INKT activation potency approximately 10-fold higher than that of the parent KRN7000, and may be advantageously linked to a biological carrier such as a protein or antibody, or vectorized into nanoparticles, e.g., virus-like particles or liposomes. This coupling may advantageously allow delivery of the iNKT activator to target cells, thereby reducing the therapeutic dose required to reach a therapeutic effect and / or reducing the potential for side effects.

[0024] For example, cetuximab is a humanized monoclonal antibody that targets EGFR (epidermal growth factor receptor), and coupling of the cetuximab antibody to an iNKT activator disclosed herein induces the known immunological effect of said antibody (ADCC (antibody-dependent cell-mediated cytotoxicity)) concomitant with activation of iNKT cells, thereby allowing the release of cytokines. Thus, a bioconjugate comprising a cetuximab antibody coupled to an iNKT activator provides a biologically combined effect against tumor targets by reactivating the immune system in close proximity to the tumor environment.

[0025] Bioconjugates comprising antibodies coupled to iNKT activators are preferably non-enzymatically cleavable linked glycoconjugates to provide greater selectivity in inducing iNKT stimulation in the tumor environment without (or only to a lesser extent) efficacy elsewhere in the body. As a result, bioconjugates comprising antibodies coupled to iNKT activators as described above reduce or suppress some of the side effects induced by delocalized activation of iNKT by the immunostimulatory agent alone, allowing selective tumor targeting to be achieved.

[0026] A first object of the present invention is therefore an iNKT activator, said iNKT activator being a compound of the following formula (II):

[0027] [ka] TIFF0007587583000007.tif17146

[0028] [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1; R1 is an alkyl group, an aryl group, a heterocyclic group, a PEG fragment -[CH2-CH2-O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer of 1 to 24), R2 represents a functional reactive group that allows coupling to a carrier D, or represents LD (where L is a linker and D is a carrier).

[0029] The iNKT activator defined above is preferably: a compound of formula (V):

[0030] [ka]

[0031] a compound of formula (VI):

[0032] [ka]

[0033] a compound of formula (VII):

[0034] [ka]

[0035] and a compound of formula (VIII):

[0036] [ka]

[0037] is selected from the group consisting of:

[0038] Another object of the present invention is a conjugate comprising at least one iNKT activator coupled to at least one carrier, comprising: (i) a compound of formula (II) as defined above [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -LD (p is an integer from 1 to 24), or an alkyl chain -(CH2) q-L-D, where q is an integer from 1 to 24, where L is a linker and D is a carrier; or (ii) an iNKT activator of formula (II) as defined above, wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer from 1 to 24), R2 represents a functional reactive group that allows coupling to said carrier D] to carrier D.

[0039] In the iNKT activator defined above or in the conjugate defined above, the carrier D is preferably a therapeutic and / or targeting agent.

[0040] The carrier D as defined above may be an antibody, an antibody fragment, a sugar, a lectin, an afftin, a growth factor, an antigen, a chemical molecule, a protein, a peptide, a glycoprotein, an aptamer, a loaded cell, a virus and / or a carbohydrate.

[0041] Another object of the present invention is to provide at least one iNKT activator as defined above, at least one conjugate as defined above, and / or a compound of formula (IV)

[0042] [ka]

[0043] The present invention is directed to a vector, e.g., a nanoparticle, comprising at least one iNKT activator comprising:

[0044] Another object of the present invention is to: (i) at least one iNKT activator comprising at least one conjugate as defined above, at least one vector as defined above, and / or at least one iNKT activator comprising a compound of formula (IV) as defined above: (ii) at least one pharma- ceutically acceptable vehicle; A pharmaceutical composition comprising:

[0045] Another object of the present invention relates to an iNKT activator comprising an iNKT activator as defined above, a conjugate as defined above, a vector as defined above, a pharmaceutical composition as defined above or a compound of formula (IV) as defined above for use as a medicament, preferably in the prevention and / or treatment of cancer, an autoimmune disease, an inflammatory disease, a viral infection, a bacterial infection and / or a parasitic disease.

[0046] Another object of the present invention is to provide a method for activating iNKT cells, comprising administering to said patient a conjugate as defined above of an iNKT activator as defined above. The present invention relates to the in vitro use of an iNKT activator comprising a vector as defined above or a compound of formula (IV) as defined above:

[0047] The present invention is further illustrated by the following figures and examples, which should not, however, be construed as limiting the scope of the present invention in any way. [Brief description of the drawings]

[0048] [Figure 1] 1 is a graph showing expression of CD1d in HeLa cells compared to its respective CD1d transfectants. [Diagram 2] Graphs showing IFN-γ, IL-2 and IL-13 secretion by IKNT cells following activation with KRN7000-loaded HEK293 (A) or HeLa (B) cells and their respective CD1d transfection models. [Diagram 3]Graph showing IFN-γ, IL-2 and IL-13 secretion by IKNT cells after activation with 6-PEG3-NH2-GalCer (2a)-loaded HEK293 (A) or HeLa (B) cells and their respective CD1d transfection models. [Figure 4] FIG. 13 is a graph showing IFN-γ secretion following activation of iNKT cells with either PBMC or non-CD1d-HEK293 cells loaded with 6-PEG3-NH2-GalCer (2a). [Diagram 5] Graph showing CD1d-dependence of iNKT cell activation observed using both HEK293 CD1d-transfected cells (left panel A) and control HEK293 cells (right panel B) as antigen-presenting cells. IL-2 secretion induced by 6-PEG3-NH2-GalCer (2a) in the presence or absence of anti-CD1d antibody. [Figure 6] FIG. 13 is an image showing RT-PCR analysis of CD1d expression in cell lines used as antigen-presenting cells (SW620, non-transfected HEK293 and HEK293 transfected to express CD1d). [Figure 7] FIG. 1 is a graph showing iNKT-induced cytotoxicity (expressed as the percentage of dead cells) in HeLa-CD1d cells after activation with 6-PEG3-NH2-GalCer (2a) or KRN7000. [Figure 8] Graph showing iNKT phenotyping. Expansion of iNKT cells in PBMCs in the presence of KRN7000 or 6-PEG3-NH2-GalCer (2a), expressed as CD8+ / CD4+ ratio. [Figure 9] Figure 1 shows cytotoxicity induced by iNKT in a HeLa-CD1d spheroid model after activation with 6-PEG3-NH2-GalCer (2a) or KRN7000. Experimental protocol (A) and cell death analysis by flow cytometry (B). [Figure 10A]Graph showing IFN-γ and IL-13 secretion by iNKT cells after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IFN-γ secretion by HeLa-CD1d cells (A). [Figure 10B] Graph showing IFN-γ and IL-13 secretion by iNKT after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IL-13 secretion by iNKT after activation with HeLa-CD1d cells (B). [Figure 10C] Graph showing IFN-γ and IL-13 secretion by iNKT cells after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IFN-γ secretion by non-CD1d HeLa cells (C). [Figure 10D] Graph showing IFN-γ and IL-13 secretion by iNKT after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IL-13 secretion by iNKT after activation with non-CD1d HeLa cells (D). [Figure 11E] Graph showing IFN-γ and IL-13 secretion by iNKT cells after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IFN-γ secretion by HEK293-CD1d cells (E). [Figure 11F]Graph showing IFN-γ and IL-13 secretion by iNKT after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IL-13 secretion by iNKT after activation with HEK293-CD1d cells (F). [Figure 11G] Graph showing IFN-γ and IL-13 secretion by iNKT cells after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IFN-γ secretion by non-CD1d HEK293 cells (G). [Figure 11H] Graph showing IFN-γ and IL-13 secretion by iNKT after activation with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c) and KRN7000. IL-13 secretion by iNKT after activation with non-CD1d HEK293 cells (H). [Figure 12] FIG. 13 is a graph showing IFN-γ secretion by iNKT following activation with HeLa cells loaded with 6-PEG3-NHAc-GalCer (2b), 6-PEG3-NH2-GalCer (2a), 6-PEG3-NHBz-GalCer (2c), 6-Mal-PEG-GalCer (3b), 6-Mal-PEG6-GalCer (3a), and KRN7000. [Figure 13] FIG. 1 is a graph showing EGFR recognition by purified cetuximab after coupling ("Cetuximab coupled") or "mock" coupling ("Cetuximab alone") reactions. [Figure 14] Graph showing IFN-γ secretion by iNKT after activation with HeLa-CD1d cells (A) or non-transfected HeLa cells (B) loaded with cetuximab + 6-PEG3-NH2-GalCer (2a) (left panel) or 6-PEG3-NH2-GalCer (2a) alone (right panel). See Tables 1 and 2 below. [Figure 15] Graph showing IFN-γ secretion by iNKT after activation with HeLa-CD1d cells (C) or non-transfected HeLa cells (D) loaded with the complex cetuximab 6-Mal-PEG6-GalCer (3a) formed by TRAUT activation (left panel) or 6-Mal-PEG6-GalCer (3a) alone (right panel). See Tables 3 and 4 below. [Figure 16] Graph showing activity of fractions A and B in iNKT cells compared to 6-Mal-PEG6-GalCer 3a after loading onto non-CD1d HeLa cells.

[0049] [Table 1] [Table 2] [Table 3] [Table 4] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] iNKT activators Thus, the present invention provides a new family of iNKT activators.

[0051] The expression "iNKT activator", also referred to as "iNKT activator", as used herein means an immunostimulator of iNKT cells, i.e. a compound capable of activating iNKT cells.

[0052] The expression "a compound capable of activating iNKT cells" as used herein means that in the presence of said compound and CD1d-expressing cells, iNKT cells express at least one cytokine or increase the expression of at least one cytokine compared to the absence of said compound.

[0053] At least one cytokine whose expression is induced or increased in the presence of an iNKT activator is a Th1 or Th2 cytokine (preferably a Th1 cytokine for cancer therapy), such as a cytokine selected from the group consisting of interferon gamma (INF-γ), TNF-α, and interleukins (such as IL-13, IL-2, IL-10, IL12, or IL4).

[0054] CD1d is a non-polymorphic major histocompatibility complex class I-like antigen-presenting molecule.

[0055] CD1d-expressing cells, also referred to as "CD1d cells", may be cells that naturally express CD1d or cells that have been transfected to express CD1d.

[0056] CD1d-expressing cells may be cells that express CD1d at low or high levels.

[0057] By "cells expressing low levels of CD1d" is meant herein that the CD1d expressed by the cells is not detectable by flow cytometry, but can be detected by RT-PCR. Cells expressing low levels of CD1d were previously considered to be "non-CD1d cells".

[0058] By "cells expressing high levels of CD1d" herein is meant that the CD1d expressed by the cells can be detected by RT-PCR and flow cytometry.

[0059] Cells expressing low levels of CD1d are, for example, tumor cells such as HeLa cells (i.e. non-transfected HeLa cells), HEK293 cells (i.e. non-transfected HEK293 cells), Meso13 cells, Meso34 cells, Meso225 cells (from breath cancer), SW116 cells or HTC116 cells (from colorectal cancer).

[0060] Non-limiting examples of cells that express high levels of CD1d are APCs (antigen presenting cells) such as monocytes, macrophages, dendritic cells, B lymphocytes, epithelial cells (especially from the colon or intestine), and any cells transfected to express CD1d.

[0061] The cells expressing high levels of CD1d may be provided in the form of PBMCs (peripheral blood mononuclear cells). PBMCs can be obtained by any method known to those skilled in the art, such as extraction from whole blood by density gradient centrifugation using Ficoll.

[0062] iNKT cells (invariant natural killer T cells) are a population of lymphocytes that recognize CD1d. INKT cells express markers derived from NK cells (such as CD16 and CD56) and T cells (such as CD3, CD4, and CD8). Their main distinctive feature is the expression of the invariant TCR, which is restricted to the CD1d molecule. This TCR recognizes only lipid and glycolipid antigens, but not peptide-like classical TCRs.

[0063] The best known natural antigen of iNKT cells is KRN7000.

[0064] Any method known to one of skill in the art can be used to assess whether a compound is an iNKT activator.

[0065] Classically, CD1d expressing cells are incubated overnight in the presence or absence of the compound to be evaluated, allowing loading of CD1d molecules. CD1d cells are then co-incubated with iNKT. A 6-hour co-culture is sufficient to allow detection of most cytokine release (such as IFN-γ, IL-13 and / or IL-2) in the supernatant. Depending on the kinetics of some late cytokines (such as IL-10), various incubation times up to 48 hours can be performed. The amount or concentration of at least one cytokine is therefore measured in the supernatant after an incubation time of 6 to 48 hours. An increase in the amount or concentration of at least one cytokine in the presence of the compound to be evaluated compared to its absence means that said compound is an iNKT activator.

[0066] When cells expressing low levels of CD1d are used in the above assay, an increase in the amount or concentration of at least one cytokine in the presence of the compound compared to its absence indicates that the compound is a potent iKNT activator.

[0067] 6-PEGm-NHR-GalCer compound The iNKT activator is a KRN7000 analog of formula (II) below, also referred to herein as the compound 6-PEGm-NHR-GalCer:

[0068] [ka]

[0069] [wherein X is a PEG fragment -[CH2-CH2-O] m - (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents H, -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1, or -CSOR1; R1 is an alkyl group, an aryl group, a heterocyclic group, a PEG fragment -[CH2-CH2-O] p-R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer of 1 to 24), R2 represents a functional reactive group allowing coupling to a carrier D, or represents LD (where L is a linker and D is a carrier), preferably comprising or consisting of:

[0070] When R2 represents a functional reactive group allowing coupling to the support D, R2 is for example N-maleimide, N3, alkyne, alkene, acryloyl, norbornene, cyclooctadiene, TCO, tetrazine, isocyanate, thiol or aldehyde.

[0071] The functional reactive groups may allow coupling to the carrier in a variety of ways, such as lysine mediated, reductive coupling to oxidized carbohydrates, cysteine ​​residue mediated, and / or hydrazone mediated, disulfide and / or peptide based bonds.

[0072] A variety of heterobifunctional linking reagents between ligands and drug conjugates have been described in the literature and can be used to couple iNKT activators to carriers via functional reactive groups.

[0073] Carrier D is, for example, as defined in the "Carrier" section below.

[0074] The linker is preferably a covalent linker.

[0075] The linker, especially the covalent linker, is preferably a non-enzymatically cleavable linker.

[0076] The linker may be, for example, a compound of formula (II) as defined above, wherein R1 is a PEG fragment -[CH2-CH2-O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q-R2 (q is an integer from 1 to 24), R2 represents a functional reactive group that allows coupling to a carrier D] is derived from a method of coupling to a carrier.

[0077] The linker may, for example, be represented by the following formula (XI):

[0078] [ka]

[0079] or a compound of formula (XIII):

[0080] [ka]

[0081] It comprises or consists of:

[0082] In one embodiment, the iNKT activator defined above is one in which R is represented by the following formula (III):

[0083] [ka]

[0084] Or the following formula (XIV):

[0085] [ka]

[0086] The present invention is characterized by having the following.

[0087] iNKT activators as defined above, in which R is R of formula (III), may in particular result from the reaction of an iNKT activator of formula (II), in which R represents H with a SM(PEG)n crosslinker.

[0088] By "SM(PEG)n linker" herein is meant a succinimide-PEGn-maleimide linker.

[0089] PEG fragment-[CH2-CH2-O] m In the formula, m is an integer of 1 to 24, preferably 1 to 20, preferably 1 to 15, and more preferably 1 to 12. For example, m may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 12, and preferably 1, 3, 6, or 12.

[0090] PEG fragment-[CH2-CH2-O] p In -R2, p is an integer of 1 to 24, preferably 1 to 20, preferably 1 to 15, more preferably 1 to 10. For example, p may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, preferably 1, 3, 6 or 12.

[0091] By "alkyl" herein is meant a straight chain hydrocarbon group containing 1 to 24 carbon atoms, preferably 1 to 12 carbon atoms, or a branched or cyclic hydrocarbon group containing 1 to 12 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, and cyclohexyl groups, preferably methyl or ethyl.

[0092] Alkyl chain -(CH2) n In the formula, n is preferably an integer of 1 to 24, for example, an integer of 1 to 20, 1 to 15, 1 to 12, or 1 to 10. For example, n may be 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, or 12, and preferably 1, 3, 6, or 12.

[0093] Alkyl chain -(CH2) q In -R2, q is preferably an integer of 1 to 24, for example, an integer of 1 to 20, 1 to 15, or 1 to 10. For example, q may be 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, or 12, and preferably 1, 3, 6, or 12.

[0094] By "branched hydrocarbon group" herein is meant a branched hydrocarbon chain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, which may be linear or branched, saturated or contain one or more double or triple bonds, which may be interrupted by one or more heteroatoms or substituted by one or more heteroatoms or one or more substituents containing heteroatoms. In this regard, "heteroatom" herein means any atom other than carbon or hydrogen, which is typically a nitrogen, oxygen or sulfur atom.

[0095] By "aryl" herein is meant a monocyclic or polycyclic aromatic hydrocarbon group that may be optionally substituted with an acid group, an amide group, an amido group, a urea group, an amine group, a thiol group, an alcohol group, an ether group, an ester group. Aryl is preferably phenyl, benzyl, naphthyl, anthracenyl. Aryl may be substituted with at least one alkyl group. A preferred example of aryl is the phenyl group.

[0096] The term "heterocyclic group" as used herein means an unsubstituted or substituted group containing 1 to 4 ring heteroatom constituent elements selected from the group consisting of nitrogen, oxygen and sulfur atoms. The heterocyclic group may be monocyclic or polycyclic.

[0097] Examples of heterocyclic groups include 3-, 4-, 5-, 6-, 7-, 8- and 9-membered rings.

[0098] Examples of five-membered rings include pyrrolidine, pyrrole, tetrahydrofuran, furan, tetrahydrothiophene, thiophene, imidazoline, imidazole, pyrazolidine, pyrazole, oxazolidine, oxazole, isoxazolidine, isoxazole, dioxolane, and dithiolane.

[0099] Examples of six-membered rings include piperidine, pyridine, tetrahydropyran, pyran, thiane, thiopyran, piperazine, diazine, morpholine, oxazine, thiomorpholine, thiazine, dioxane, dioxine, dithiane, dithiin, hexahydro-1,3,5-triazine, triazine, trioxane, trithiane, tetrazine, pentazine, triazole, furazan, oxadiazole, thiadiazole, dioxazole, dithiazole, tetrazole, oxatetrazole, thiatetrazole, or pentazole.

[0100] The iNKT activators of formula (II) as defined above are advantageously soluble in aqueous methanol and / or DMSO solvents.

[0101] A preferred iNKT activator is, for example, a compound represented by the following formula (IV):

[0102] [ka]

[0103] has.

[0104] The iNKT activators of formula (IV) induce high CD8+ responses, resulting in high cytotoxic responses.

[0105] Another preferred iNKT activator has, for example, the following formula (V):

[0106] [ka]

[0107] has.

[0108] Another preferred iNKT activator has, for example, the following formula (VI):

[0109] [ka]

[0110] has.

[0111] Another preferred iNKT activator has, for example, the following formula (VII):

[0112] [ka]

[0113] has.

[0114] Another preferred iNKT activator has, for example, the following formula (VIII):

[0115] [ka]

[0116] has.

[0117] Thus, the iNKT activator is preferably selected from the group consisting of compounds of formula (IV), compounds of formula (V), compounds of formula (VI), compounds of formula (VII), and compounds of formula (VIII) as defined above.

[0118] The iNKT activators defined above can be, for example, a PEG fragment, -[CH2-CH2-O] p -LD (p is an integer from 1 to 24), or an alkyl chain -(CH2) q When R2 represents -LD (q is an integer from 1 to 24) it may comprise a carrier D or may be further coupled to a carrier D, for example when R2 represents a functional reactive group.

[0119] The iNKT activator may be provided in the form of a vector comprising said iNKT activator, in particular as defined below.

[0120] The iNKT activators may be provided in the form of a pharmaceutical composition, as defined in particular below.

[0121] The iNKT activators can be obtained, for example, by the methods defined below.

[0122] Method for producing compound 6-PEGm-NHR-GalCer The present invention also relates to a method for producing an iNKT activator of formula (II) as defined above, comprising the steps of: Optionally, galactose and phytosphingosine are reacted to produce a compound of formula (IX):

[0123] [ka]

[0124] Obtaining a compound having the formula The reaction is preferably: preparing a glycosyl donor by orthogonal protection and anomeric activation of galactose; preparing a glycosyl acceptor by orthogonal protection of phytosphingosine followed by N-acylation and deprotection steps; A step of glycosylating and deprotecting a primary hydroxyl group; ), and - reacting the compound of formula (IX) with N3-CH2-CH2-PEG3-N=C=O to give, after hydrogenation, the compound of formula (X):

[0125] [ka]

[0126] obtaining a compound having the formula: optionally with a compound of formula (X) sodium methoxide to produce a compound of formula (IV), acetic anhydride followed by sodium methoxide to produce a compound of formula (V), or Phenylacetyl chloride followed by sodium methoxide to produce the compound of formula (VI) and reacting - optionally reacting a compound of formula (IV) with a SM(PEG)6 crosslinker to produce a compound of formula (VII) or with a SM(PEG)2 crosslinker to produce a compound of formula (VIII); The present invention also relates to a method, comprising:

[0127] Exemplary methods for producing iNKT activators of formula (IV), (V), (VI), (VII) or (VIII) are further detailed in Example 1.

[0128] Carrier The present invention also relates to an iNKT activator as defined above, comprising at least one carrier or coupled to at least one carrier.

[0129] The carrier is also referred to herein as "Carrier D" or "D".

[0130] When an iNKT activator comprises or is coupled to one or at least one carrier D, the iNKT activator is also referred to as a complex, conjugate, bioconjugate or glycoconjugate.

[0131] A carrier may be any compound that can improve the efficiency and / or stability and / or half-life of an iNKT activator, that can localize an iNKT activator (e.g., a labeling agent), that can specifically deliver an iNKT activator (e.g., a targeting agent), and / or that has therapeutic activity (e.g., a therapeutic agent).

[0132] The carrier is preferably a targeting agent and / or a therapeutic agent.

[0133] A targeting agent is any compound that allows the iNKT activator defined above to be delivered to a target cell and / or to an area surrounding or nearby the target cell. A targeting agent is, for example, a compound that binds to a receptor expressed by CD1d cells.

[0134] For example, in the frame of cancer prevention and / or treatment, the targeting agent may specifically bind to tumor cell receptors, in particular those expressed on CD1d cells, or to cells present in the tumor environment.

[0135] A therapeutic agent is any compound that has a therapeutic effect, in particular a preventive and / or curative therapeutic effect. The therapeutic agent preferably has a therapeutic effect against the same disease, but preferably through a different mechanism of action than iNKT.

[0136] The targeting agent and / or therapeutic agent may be, for example, a protein, a peptide, a glycoprotein, an aptamer, a virus, a chemical molecule, preferably a small chemical molecule, or a carbohydrate.

[0137] Non-limiting examples of targeting agents are antibodies, antibody fragments (Fab, scFv, nanobodies, etc.), sugars, lectins, afftins, growth factors, or chemical molecules that specifically bind to a target.

[0138] Non-limiting examples of therapeutic agents are antigens, such as bacterial or viral antigens, antibodies, antibody fragments, or chemical molecules (eg, synthetic bioactive molecules).

[0139] The expression "small chemical molecule" means herein a chemical molecule having a molecular weight below 500 kDa.

[0140] The antigen as defined above may be a carbohydrate antigen or a peptide antigen.

[0141] Thus, a given carrier may be both a therapeutic agent and a targeting agent, such as in the case of an antibody.

[0142] The carrier may be an internalizing carrier or a non-internalizing carrier.

[0143] By "internalizing carrier" herein is meant a carrier that, upon binding to a target cell, is internalized into said target cell.

[0144] An internalizing carrier as defined above is preferably both a therapeutic agent and a targeting agent.

[0145] The internalizing carrier as defined above is preferably an antibody.

[0146] In the case of a conjugate comprising at least one iNKT activator coupled to at least one internalization carrier, the internalization carrier is preferably capable of internalizing said conjugate.

[0147] When a conjugate comprising at least one iNKT activator coupled to at least one internalization carrier is internalized into a target cell, the iNKT activator is preferably then released from the conjugate, thereby enabling loading onto CD1d molecules, presentation on the surface of the target cell, and iNKT stimulation.

[0148] When the carrier is an antibody, the antibody is preferably a monoclonal antibody.

[0149] The monoclonal antibodies are preferably human or humanized monoclonal antibodies.

[0150] An antibody as defined above may be a monospecific antibody or a multispecific antibody, such as a bispecific antibody.

[0151] The antibody as defined above is capable of specifically binding to at least one receptor expressed on tumor cells.

[0152] Non-limiting examples of antibodies that can be used as carriers are anti-EGFR antibodies (such as cetuximab or panitumumab), anti-HER2 antibodies (such as trastuzumab).

[0153] Anti-EGFR antibodies such as cetuximab or panitumumab are examples of internalizing carriers.

[0154] Thus, the present invention also relates to a conjugate comprising at least one iNKT activator as defined above coupled to at least one carrier as defined above, preferably via a linker between the iNKT activator and the carrier.

[0155] The carrier of the conjugate is preferably a therapeutic and / or targeting agent.

[0156] The coupling between the iNKT activator and the carrier may be covalent.

[0157] The present invention particularly relates to a conjugate as defined above, in which at least one iNKT activator is covalently bound to at least one carrier, preferably in a non-enzymatically cleavable manner.

[0158] One, two, three or at least four iNKT activators may be coupled to one, two, three or at least four carriers to form a conjugate.

[0159] When a conjugate as defined above comprises at least two iNKT activators, the iNKT activators may be the same or different.

[0160] When the conjugate defined above comprises at least two carriers, the carriers may be the same or different.

[0161] A preferred conjugate is a conjugate as defined above, which comprises at least one iNKT activator and one carrier (i.e., a one-molecule carrier), and in which the iNKT activator is preferably linked to the carrier, optionally via a linker.

[0162] The linker present in the conjugate can result, for example, from the method of coupling the iNKT activator to the carrier.

[0163] The present invention relates, for example, to a conjugate comprising at least one (preferably one or two) iNKT activator coupled to at least one (preferably one) carrier, (i) A compound of formula (II)

[0164] [ka]

[0165] [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -LD (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -L-D, where q is an integer from 1 to 24, where L is a linker and D is a carrier; or (ii) an iNKT activator of formula (II) above, where X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p represents a functional reactive group allowing coupling to the carrier D] to a carrier D.

[0166] As a non-limiting example, coupling of a carrier which is an antibody, protein, peptide, or glycoprotein can be obtained by reacting Traut's reagent with said carrier to obtain a Traut-thiol-activated carrier, and then coupling the Traut-activated carrier to an iNKT activator, in particular an iNKT activator of formula (II), where R is a group of formula (III) as defined above, to obtain a conjugate comprising an iNKT activator coupled to the carrier.

[0167] Traut's reagent is 2-iminothiolane.

[0168] Further preferred conjugates are those defined above which comprise one iNKT activator (i.e., one molecule of iNKT activator) and one carrier (i.e., one molecule of carrier), wherein the iNKT activator is linked to the carrier, preferably via a linker.

[0169] Another preferred conjugate is a conjugate as defined above, comprising two iNKT activators (i.e., two molecules of iNKT activators) and one carrier (i.e., one molecule of carrier), each iNKT activator being linked to the carrier, preferably via a linker.

[0170] Thus, a conjugate as defined above comprising at least one (preferably one, two or at least two) iNKT activator coupled to at least one (preferably one) carrier comprises a compound of formula (II)

[0171] [ka]

[0172] [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n- (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -LD (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -LD (q is an integer from 1 to 24), where L is a linker and D is a carrier). Thus, the compound of formula (II) defined above is a compound of an iNKT activator coupled to a carrier D via a linker L. The compound of formula (II) defined above may be coupled to at least another compound via a carrier D. The other compound coupled to carrier D is preferably an iNKT activator. The other compound coupled to carrier D is preferably the same as the iNKT activator coupled to carrier D via a linker L of formula (II) defined above.

[0173] Thus, the conjugate defined above may have the following structure: (iNKT activator 1)-(linker L1)-(carrier D)-(linker L2)-(iNKT activator 2) (wherein L1 and L2 are preferably identical and / or iNKT activators 1 and 2 are preferably identical).

[0174] Thus, a conjugate as defined above comprising at least one (preferably one, two or at least two) iNKT activator coupled to at least one (preferably one) carrier comprises at least one (e.g. one, two or at least two) iNKT activator of formula (II):

[0175] [ka]

[0176] [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), alkyl chain -(CH2) n- (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONR1, -COOR1, -CSR1, -CSNR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer from 1 to 24), R2 represents a functional reactive group that enables coupling to a carrier D] can be obtained by coupling to one carrier D.

[0177] vector The iNKT activator as defined above or the conjugate as defined above may be provided in the form of a vector comprising said iNKT activator or conjugate.

[0178] The vector may be any delivery vehicle capable of encapsulating the compound.

[0179] The vector may be, for example, a nanoparticle, such as a liposome (eg, a polymeric or lipidic liposome), a virus-like particle (VLP), a dendrimer, a micelle, a nanoemulsion, and a nanosuspension.

[0180] Therefore, the present invention also relates to a vector comprising at least one iNKT activator as defined above, or at least one conjugate as defined above.

[0181] The iNKT activator or conjugate may be present inside the vector, particularly in the case of a liposome, dendrimer, micelle, nanoemulsion or nanosuspension.

[0182] Alternatively, the iNKT activator or conjugate may be on the surface of the vector such that it can bind directly to CD1d expressed by the cells.

[0183] The vector may further comprise at least one targeting agent as defined above and / or at least one therapeutic agent as defined above.

[0184] Pharmaceutical Compositions The iNKT activator as defined above, the conjugate as defined above and / or the vector as defined above may be formulated in a pharmaceutical composition.

[0185] Thus, the present invention also relates to a pharmaceutical composition comprising (i) an iNKT activator as defined above, or a conjugate as defined above, or a vector as defined above, and (ii) optionally a pharma- ceutically acceptable vehicle.

[0186] The expression "pharmaceutically acceptable vehicle" is meant to encompass any vehicle, which does not interfere with the effectiveness of the biological activity of the active ingredient and preferably is not toxic to the host to which it is administered.

[0187] The pharma- ceutically acceptable vehicle may be prepared by any method known to those skilled in the art.

[0188] Suitable pharma- ceutically acceptable vehicles may include excipients and auxiliary agents that facilitate the processing of the active compound into a pharma- ceutically usable preparation. Suitable pharma-ceutically acceptable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, USA, 1985), a well-established reference text in the field. Pharmaceutically acceptable vehicles can be routinely selected according to the mode of administration, solubility and stability of the iNKT activator. For example, a formulation for intravenous administration may include a sterile aqueous solution that may also contain buffers, diluents and / or other suitable additives. The use of biomaterials and / or other polymers for drug delivery has been disclosed in the literature, as have different approaches and models for validating a particular mode of administration.

[0189] The pharmaceutical composition may be a liquid, such as a solution or a suspension.

[0190] The iNKT activator as defined above is preferably present in the pharmaceutical composition in an amount effective to achieve the intended purpose, which may depend, for example, on the condition of the mammal to which it is intended to be administered (e.g., weight, age, sex, health, current treatments (if any), and frequency of treatments), the mode of administration, and the type of formulation.

[0191] For example, the pharmaceutical composition may contain 5 μg to 50 mg of iNKT activator, preferably 10 μg to 40 mg of iNKT activator, preferably 50 μg to 20 mg of iNKT activator, preferably 75 μg to 10 mg, preferably 100 μg to 5 mg, and more preferably 100 μg to 1 mg of iNKT activator.

[0192] The pharmaceutical composition may include at least one additional active ingredient.

[0193] This additional active ingredient may be, for example, a therapeutic agent, a drug or a prodrug, as defined above.

[0194] The pharmaceutical composition may be a vaccine.

[0195] When the pharmaceutical composition defined above is a vaccine, said composition may comprise at least one iNKT activator and at least one antigen, such as a viral or bacterial antigen.

[0196] In one embodiment, the pharmaceutical composition is presented in a unit dosage form to facilitate accurate dosing.The term "unit dosage form" refers to a physically separate unit suitable as a unit dosage form for human subjects or other mammals, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect in association with a suitable pharmaceutical vehicle.Exemplary unit dosage forms include prefilled, premeasured ampoules or syringes of liquid pharmaceutical compositions.In such compositions, iNKT activators are usually minor components.

[0197] The present invention further provides a kit comprising a pharmaceutical composition as defined above and instructions concerning the mode of administration, which may, for example, indicate the medical indication, the route of administration, the dosage and / or the patient population to be treated.

[0198] iNKT activators, conjugates or vectors for use as medicines The present invention particularly relates to an iNKT activator as defined above, a conjugate as defined above, or a vector as defined above for use as a medicament, in particular in immunotherapy, e.g. for the prevention and / or treatment of any disease requiring the stimulation of an immune response, in particular in a subject in need thereof.

[0199] The present invention also relates to a method for the prevention and / or treatment of a disease requiring stimulation of an immune response in a subject in need thereof, comprising the step of administering to said subject an iNKT activator as defined above, a conjugate as defined above, or a vector as defined above.

[0200] By "disease requiring the stimulation of an immune response" herein is meant a disease whose prevention and / or treatment requires or is ameliorated by the enhancement or initiation of an immune response.

[0201] The subject can be, for example, a human or non-human mammal.

[0202] A human is also referred to as an "individual" or a "patient."

[0203] The human may be of any age, eg, infant, child, adolescent, adult, elderly, and of any gender.

[0204] The non-human mammal is preferably a cat, dog, rabbit, primate, mouse or rat.

[0205] The subject being treated may be suffering from a disease requiring the stimulation of an immune response or may be susceptible to contracting a disease requiring the stimulation of an immune response.

[0206] Prevention of diseases which require the stimulation of an immune response includes vaccination.

[0207] The disease requiring stimulation of an immune response may for example be selected from the group consisting of cancer, an autoimmune disease, an inflammatory disease, a viral infection, a bacterial infection, a parasitic disease and / or any immunodeficiency condition.

[0208] The cancer that may be prevented and / or treated by the present invention may be any cancer whose cells express CD1d, such as lung cancer, metastatic cancer, neck skin cancer, head cancer, breast cancer, stomach cancer, colon cancer, adenocarcinoma and / or cold tumors.

[0209] The autoimmune disease which may be prevented and / or treated according to the present invention may be, for example, celiac disease, type 1 diabetes, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis or systemic lupus erythematosus.

[0210] The inflammatory disease which may be prevented and / or treated according to the invention may be, for example, chronic peptic ulcer, tuberculosis, rheumatoid arthritis, periodontitis, ulcerative colitis or Crohn's disease.

[0211] The viral infection may be any infection caused by a virus, such as, for example, a Hepatitis C infection or a Hepatitis B infection.

[0212] The bacterial infection may be, for example, any infection caused by bacteria.

[0213] The parasitic disease may be, for example, any infection caused by a parasite.

[0214] iNKT activators are defined above.

[0215] In particular, the iNKT activator can be obtained by the method defined above.

[0216] The iNKT activator, conjugate or vector may be provided in the form of a pharmaceutical composition as defined above.

[0217] The iNKT activator may comprise a carrier as defined above or may be coupled to a carrier as defined above.

[0218] The use of a targeting agent as a carrier advantageously allows for delivery of an iNKT activator to target cells that express both the targeting agent's ligand and CD1d, thereby allowing for a reduction in potential side effects and / or the dose required to achieve a therapeutic effect.

[0219] For example, for the prevention and / or treatment of cancer, iNKT activators are advantageously coupled to agents that target specific receptors present in the tumor environment, such as specific receptors on the tumor cells themselves, preferably specific receptors on tumor cells expressing CD1d, or specific receptors on cells found specifically in the tumor periphery.

[0220] The carrier is preferably an antibody or an antibody fragment as defined above.

[0221] For example, a conjugate comprising at least one iNKT activator as defined above coupled to an EGFR antibody may be used or administered for the prevention and / or treatment of cancer, preferably colorectal cancer and / or respiratory cancer.

[0222] For example, a conjugate comprising at least one iNKT activator as defined above coupled to an EGFR antibody may be used or administered for the prevention and / or treatment of cancer, preferably colorectal cancer, respiratory cancer and / or adenocarcinoma.

[0223] For example, a conjugate comprising at least one iNKT activator as defined above coupled to a HER2 antibody may be used or administered for the prevention and / or treatment of cancer, preferably breast cancer, gastric cancer, colon cancer and / or adenocarcinoma.

[0224] The conjugate defined above comprising anti-EGFR antibody can be advantageously used or administered for the prevention and / or treatment of cancer in a subject in need thereof, regardless of whether this subject has at least one Kras and / or N-Ras mutation.In contrast, cetuximab alone or panitumumab alone is less efficient for the treatment of patients with Kras and / or N-Ras mutations, and is only used for the treatment of subjects with wild-type Kras and N-Ras genes.In the framework of the present invention, anti-EGFR is actually mainly used as a targeting agent.

[0225] Thus, the conjugates as defined above comprising an anti-EGFR antibody can be advantageously used or administered for the prevention and / or treatment of cancer in any subject in need thereof, in particular in subjects resistant to treatment with an anti-EGFR antibody alone.Thus, moreover, the conjugates as defined above comprising an anti-EGFR antibody can be advantageously used or administered without the need to previously look for the presence of a Kras or N-Ras mutation.

[0226] Conjugates comprising at least one iNKT activator as defined above coupled to an afftin or a chemical molecule, preferably a small chemical molecule, wherein said afftin or chemical molecule is capable of recognizing a bacterial or viral compound (such as a bacterial or viral antigen), may be used or administered for the prevention and / or treatment of bacterial or viral infections.

[0227] iNKT activators are preferably used or administered in a therapeutically effective amount.

[0228] By "therapeutically effective amount" herein is meant an amount sufficient to achieve initiation or amplification of an immune response. Such an effective amount can be routinely determined by one of ordinary skill in the art. The amount of iNKT activator actually administered will typically be determined by a physician in light of the relevant circumstances, including the condition to be prevented or treated, the selected route of administration, the actual agent administered, the age, sex, weight and response of the individual subject, the severity of the subject's symptoms, and the like. It will also be understood by one of ordinary skill in the art that the dosage may depend on the stability of the agent administered.

[0229] The effective amount may also vary depending on the therapeutic agent, drug and / or prodrug with which the iNKT activator defined above may be co-administered.

[0230] A therapeutically effective amount includes an amount in which any toxic or detrimental effects of the iNKT activator are outweighed by the therapeutically beneficial effects.

[0231] The iNKT activators, conjugates, vectors or pharmaceutical compositions may be used or administered by any suitable route, such as by arterial, venous, tissue, intraperitoneal, intranasal, intracerebral, intraocular and / or oral routes.

[0232] Administration of the iNKT activator, conjugate, vector, or pharmaceutical composition comprising same may be accomplished in a single dose or in multiple doses, which may be injected simultaneously, separately or sequentially.

[0233] The iNKT activator, conjugate, vector or pharmaceutical composition may be administered in an amount ranging from 10 g to 4800 μg / m 2 Body surface, e.g., iNKT activator 20μg~2000μg / m 2 Body surface, e.g., iNKT activator 20μg~500μg / m 2 Body surface, or iNKT activator 50μg-500μg / m 2 For example, they may be used or administered in therapeutic doses on the surface of the body.

[0234] In vitro use of iNKT activators The present invention also relates to the in vitro use of an iNKT activator as defined above, a conjugate as defined above, or a vector as defined above for activating iNKT cells, in particular for inducing or increasing the expression of at least one cytokine as defined above.

[0235] The present invention particularly relates to the in vitro use of an iNKT activator as defined above, a conjugate as defined above, or a vector as defined above for inducing stimulation and / or amplification of an immune CD1d-dependent iNKT response.

[0236] The iNKT activators defined above, the conjugates defined above, or the vectors defined above can therefore be used in any assay in which in vitro stimulation and / or amplification of an immune CD1d-dependent iNKT response is required. EXAMPLES

[0237] Example 1 6-PEG-NHR-GalCer 2 and 6-Mal-PEG n Synthesis of -GalCer3 Compounds 6-PEG3-NHR-GalCer and 6-Mal-PEG of formula IV(2a), V(2b), VI(2c) (R=H, Ac, and PhCH2CO, respectively) n The synthesis of -GalCer VII (3a) and VIII (3b) is based on conventional chemical routes described in the literature.

[0238] The synthesis of the key protected 6" OH-Galcer intermediate for generating 6-PEG3-NHR-GalCer 2 and 3 was achieved from galactose and phytosphingosine precursors by established chemical procedures with minor modifications (see Scheme 1 below).

[0239] [ka]

[0240] a) PhSH, BF3.Et2O, DCM, MS4Å; c) MeONa / MeOH; d) TBDPSCl, Et3N, Pyr.; e) NaH, BnBr, DMF / THF; f) NBS, DAST, DCM, -15°C.

[0241] [ka]

[0242] a) Boc2O, Et3N, DMF b) TBDPSCl, imidazole, DMAP, DMF c) Ac2O, Pyr, DMAP; d) TFA, DCM, 0°C e) cerotic acid, PyBOP, Et3N, DCM, f) HF.pyridine, THF g) SnCl2, AgClO4, THF / Et2O, MS 4Å h) TBAF.3H2O, THF i) NIS, TfOH, DCM / Et2O / THF, 0°C then room temperature.

[0243] Scheme 1 From the protected 6"-OH-Galcer, all 6-PEG3-NHR-GalCer 2 and 6-Mal-PEG n -GalCer 3 is accessible (see Schemes 2 and 3 below).

[0244] [ka]

[0245] a) ClCO2Et, Et3N, THF, 0°C to room temperature, 30 min, then NaN3, H2O / THF, 0°C to room temperature, 1 h, quantitative b) Toluene, 90°C, 15 min c) DABCO, toluene, reflux, 4 h, 86%

[0246] [ka]

[0247] a) H2, Pd / C HCl, (4M in dioxane), DCM b) MeONa, MeOH, room temperature c) Ac2O, DMAP, pyridine, room temperature d) PhCH2COCl, NEt3, DCM, room temperature

[0248] Scheme 2

[0249] [ka]

[0250] Scheme 3

[0251] Example 2 6-PEG3-NHR-GalCer2 and 6-Mal-PEG n Activation of iNKT by -GalCer 3 6-PEG3-NHR-GalCer 2 and 6-Mal-PEG activate iNKT n To analyze the capacity of -GalCer 3, several types of presenting cells were used, such as HEK293 or HeLa cells transfected to express the CD1d molecule on their membrane. Since it is known that presentation of glycolipids to iNKT cells is dependent on CD1d, non-transfected cells were also used as a "seemingly" negative control.

[0252] CD1d expression in HEK293 and HeLa+ / - CD1d was analyzed by flow cytometry (Figure 1). Cells were labeled with anti-CD1d-FITC or the relevant isotype control for 20 min, washed and read on an Accuri C6 flow cytometer. As shown in Figure 1, in both cases non-transfected cells appeared negative, especially when compared to their CD1d-transfected counterparts.

[0253] These cells were then used as antigen presenting cells (APCs) to compare the iNKT cell activation potency of standard α-GalCer (KRN7000) ligand with that of the analog 6″ modified ligand bearing the amino PEG-linked arm 6-PEG3-NH2-GalCer 2a. After overnight co-incubation at various concentrations, APCs were loaded with glycolipids. The next day, cells were washed and co-cultured with iNKTs (1 iNKT to 2 APCs). After 6 hours, supernatants were collected and cytokine secretion (IFN-γ and IL-2 for Th1 panel and IL-13 for Th2 panel) was measured by ELISA (Figures 2 and 3).

[0254] First, the standard ligand, KRN7000, was presented to iNKT cells by HEK293 (Figure 2A) or HeLa (Figure 2B) cells and the relevant CD1d transfected model. In both cases, KRN7000 induced IFN-γ, IL2 and IL13 release in the presence of high expression of CD1d in CD1d transfected cells (LogIC50 summarized in table 1), highlighting the CD1d dependency of glycolipid recognition by iNKT cells. When 6-PEG3-NH22-GalCer 2a was used (Figures 3A and 3B), we observed much stronger IFN-γ, IL13 and IL-2 secretion, almost 100-fold higher than KRN7000 (see comparison in table 1).

[0255] More surprisingly, however, in the absence of CD1d (tests performed with non-CD1d Hela and HEK293 cells), a significant dose-response secretion of cytokines was still detected, whereas KRN7000 remained very poorly active or ineffective. These unexpected results were not observed when SW620 cells were used as a control (absence of CD1d, data not shown).

[0256] A similar cytokine release profile was observed for IFN-γ released from PBMC cells, which represent a closer human medium compared to non-CD1d- HEK293 cells (see FIG. 4).

[0257] The results indicate that 6-PEG3-NH2-GalCer 2a appears to be one of the most potent activators of h-iNKT known to date. These biological outcomes of 6-PEG3-NH2-GalCer 2a make this novel candidate extremely interesting in the context of immunotherapy for cancer for the development of clinical trials with KRN7000.

[0258] [Table 5]

[0259] Example 3 "Non-CD1d" tumor cells: a false paradigm In light of the interesting observation of INKT activation in "non-CD1d" tumor cells, we investigated how well 6-PEG3-NH2-GalCer 2a could activate iNKT cells in what appeared to be CD1d-negative cells. Therefore, non-transfected HeLa and HEK293 cells were used as autoantigen-presenting cells. It was hypothesized that there exists a pool of CD1d on the surface of non-CD1d tumor cells, even if very low, that is sufficient to be recognized by the very potent 6-PEG3-NH2-GalCer a2 glycolipid and enable iNKT activation. On the other hand, KRN7000 does not achieve this goal.

[0260] We then checked whether iNKT cell activation could be brought about by the extremely low expression of CD1d on the relevant non-CD1d tumor cells, which cannot be detected by flow cytometry. For this purpose, the same activation experiment was performed, but in the presence of anti-CD1d antibodies. HEK293 cells and HEK293-CD1d were loaded with 6-PEG3-NH2-GalCer a2 as described previously. Before co-culture with iNKT cells, the loaded presenting cells were co-incubated with anti-CD1d antibodies for 1 h, and iNKT were added directly to the suspension and co-cultured for 6 h before cytokine analysis in the supernatant (ELISA). If the activation signal was brought about by presentation of modified glycolipids through CD1d, it was expected to observe a disturbance, or at least a reduction, of cytokine secretion after blocking the signal with anti-CD1d antibodies.

[0261] When CD1d-HEK293 positive cells were used, only incomplete inhibition was observed in the presence of the antibody (see Figure 5A). This may be due to the extremely high potency of 6-PEG3-NH2-GalCer 2a combined with the high level of CD1d expression in the transfected cells. However, when "non-CD1d" cells were used, the cytokine signal was almost completely eliminated (see Figure 5B). This experiment clearly suggests the presence of a previously unknown low level of CD1d molecules in non-transfected HEK293 cells.

[0262] To confirm this hypothesis, the most sensitive method to detect low signals of CD1d is to determine the ARN expression of CD1d using PCR. Three cell lines were analyzed: HEK293 with CD1d as a positive control, SW620 as a negative control that does not activate iNKT cells with 6-PEG3-NH2-GalCer 2a, and non-transfected HEK293 cells (see Figure 6).

[0263] As shown in Figure 6, HEK293-CD1d positive cells displayed a strong CD1d signal, whereas SW620 cells were found to be CD1d negative, consistent with their inability to serve as antigen presenting cells for 6-PEG3-NH2-GalCer compound 2a. Interestingly, a significant signal was detected for non-CD1d-HEK293 cells. This confirmed that, contrary to the paradigm, these cells express low levels of CD1d that are 100-1000 times more potent, not sufficient to induce iNKT activation using KRN7000, but sufficient to activate by 6-PEG3-NH2-GalCer 2a.

[0264] These results clearly demonstrate that 6-PEG3-NH2-GalCer 2a unexpectedly exhibits a similar dependency on CD1d presentation, but is far more potent than KRN7000.

[0265] Another interesting point is the ability of 6-PEG3-NH2-GalCer 2a to remain highly efficient even at very low levels of CD1d expression on tumor cells, which redefines the concept of non-CD1d cells in anti-cancer therapy, because these results showed that tumor cells previously considered to be CD1d negative constitutively express trace levels of CD1d sufficient to induce iNKT cell activation when loaded with the highly potent 6-PEG3-NHR-GalCer glycolipid.

[0266] This suggests that cancer cells may be used as presenting cells to activate iNKT cells in the presence of these potent glycolipids, circumventing the need for classical CD1d antigen-presenting cells (such as monocytes, macrophages or dendritic cells and B lymphocytes) to initiate immune responses in the tumor environment. To confirm this finding, a variety of other colon, lung, embryonic kidney, and cervical cancer cell lines were screened by RT-PCR to identify cell lines expressing low levels of CD1d and to confirm their ability to self-present novel potent iNKT agonists (see Table 6).

[0267] [Table 6]

[0268] Furthermore, 6-PEG3-NH2-GalCer 2a is not only one of the strongest activators of iNKT cells known for cytokine secretion, but also can induce iNKT cytotoxicity superior to KRN7000. iNKT were co-cultured with HeLa CD1d transfected cells in the presence of various concentrations of glycolipids for 24 hours, and then the mortality of target HeLa-CD1d cells was analyzed by flow cytometry. As shown in Figure 7, 6-PEG3-NH2-GalCer 2a appears to be at least 10 times more efficient than KRN7000 in inducing cytotoxicity.

[0269] To confirm that either CD4 or CD8 orientation of immune responses can be induced using KRN7000 versus 6-PEG3-NH2-GalCer 2a, a comparison study was performed (see FIG. 8). PBMCs were cultured in the presence of high doses of KRN or 6-PEG3-NH2-GalCer 2a, and after 10 days, the iNKT phenotype was analyzed by flow cytometry. Quite interestingly, 6-PEG3-NH2-GalCer 2a appears to induce a higher cytotoxic CD8+ response from PBMC cells than KRN7000, which does not seem to distinguish between CD4+ and CD8+ cell stimulation. This result already confirmed the immune cytotoxicity efficiency of 6-PEG3-NH2-GalCer 2a via iNKT stimulation. This ability was confirmed by another cytotoxicity assay (72 hours) in another more complex and more resistant model, the HeLa-CD1d 3D spheroid model (Figure 9A). Once again, 6-PEG3-NH2-GalCer 2a appears to be more efficient than KRN7000 in inducing cell death (preliminary data, see Figure 9B).

[0270] Example 4 Evaluation of 6-PEG3-NH2-GalCer 2a and 6-PEG3-NHR-GalCer 2b and 2c analogues To better understand the surprising iNKT stimulating ability of 6-PEG3-NH2-GalCer 2a and the influence of the terminal amino functionality of the 6"-O-PEG substituted KRN7000 analogues, we envisaged blocking the NH2 group with acetate 2b and benzocarbonyl 2c groups. We hoped to establish whether the presumed stabilization of the ternary CD1d-tumor cell / 6-PEG3-NH2-GalCer / TCR-iNKT complexes was explained by the presence of a free amine at the end of the spacer 14 atom chain or whether the PEG sequence allows some mutations at the terminal group without loss of performance.

[0271] Thus, two new protected NHR analogs of 6-PEG3-NH2-GalCer 2a were prepared (where R is the acetate 6-PEG3-NHAc-GalCer 2b or the benzoyl group 6-PEG3-NHCOBn-GalCer 2c). Two activated derivatives, 6-Mal-PEG, were attached to the same terminus for the purpose of engaging in conjugation with biological carriers. n -GalCer 3a and 3b (n=6 or 1, respectively) were also prepared.

[0272] Both terminal NHR protecting groups were thought to avoid and alter interactions that may occur with CD1d-tumor cells and TCR receptors in the presence of a free NH2 terminal group.

[0273] The 6-PEG3-NH2-GalCer analog of 2a was evaluated for INF-γ secretion and IL13 stimulation in transfected CD1d and non-CD1d Hela and HEK293 cells (see Figures 10 and 11).

[0274] Depending on the model, 6-PEG3-NHAc-GalCer 2b was approximately 10-100 times more potent (LogIC50>-12 for IFN-γ in HeLa CD1d-transfected cells) than PEG3-NH2-GalCer 2a (LogIC50=-10.89) itself in activating iNKT in CD1d-transfected tumor cells, and approximately 10 times more potent than KRN7000 (LogIC50=-8.8). 4 While appearing to be higher, 6-PEG3-NHCOBn-GalCer 2c has a closer cytokine secretion potency than KRN7000.

[0275] These data confirm that PEG3-NH2-GalCer 2a and 6-PEG3-NHAc-GalCer 2b are still nearly as potent as KRN7000 in activating iNKT (by 2 and 3 logs (Figures 11G and H)), but 6-PEG3-NHCOBn-GalCer 2c still has the same profile of activity as KRN7000 in non-CD1d- tumor cells.

[0276] These data indicate that the activity of PEG3-NHR-GalCer derivatives is sensitive to the nature of the NHR end group, with R=acetate exhibiting iNKT stimulatory potency in the near pM range in transfected tumor cells and, more interestingly, in the sub-nM range in non-CD1d- tumor cells.

[0277] Comparative studies were also performed to evaluate the mutations induced by the introduction of PEG-maleimide (n=1 and 6) fragments at the terminal positions of 6-PEG3-NH2-GalCer 2a (see FIG. 12).

[0278] The data show that 6-Mal-PEG6-GalCer 3a, which displays a maleimide-activating functional group, slightly reduces the activation of iNKT cells, but is nearly 10-fold higher than KRN7000).

[0279] Nonetheless, these data already make the novel 6-Mal-PEG6-GalCer 3a a candidate for conjugation with therapeutic antibodies or other biocarriers to induce cumulative biological anticancer cytokine release and cytotoxic effects of the carrier close to the tumor environment.

[0280] Example 5 Details of the non-enzymatically cleavable GalCer / cetuximab conjugate We optimized the synthesis of 6-Mal-PEG6-GalCer 3a from 6-PEG3-NH2-GalCer 2a, which represents a long bait featuring a suitable reactive maleimide end group (dotted box) aimed at reacting in situ with the trout-activated cetuximab antibody to achieve a covalent bond between the two partners (Scheme 4).

[0281] A one-pot process was also successfully experimented to obtain GalCer / cetuximab conjugate C1 from 6-PEG3-NH2-GalCer 2a without purifying the maleimide 6-Mal-PEG6-Galcer intermediate 3a. For this purpose, 6-PEG3-NH2-GalCer 2a was dissolved in phosphate buffer (PB) containing 10% DMSO at 20°C, and then directly reacted with maleimide-PEG6-succinimide linker (a length of 6 PEG units was selected according to our previous results) to obtain 6-Mal-PEG6-Galcer 3a, which was directly incubated with the activated trout cetuximab partner, leading to GalCer / cetuximab conjugate C1.

[0282] [ka]

[0283] (i) Coupling of glycolipids to cetuximab and purification a) Coupling conditions For coupling to cetuximab the following conditions were maintained:

[0284] First, cetuximab was modified with TRAUT functional groups at a ratio of 100 TRAUT molecules per antibody, allowing the addition of at least four TRAUT functional groups to cetuximab as determined by a previously investigated Ellman reaction (data not shown). The mixture was washed and then incubated with 1 / 1 equivalents of 6-Mal-PEG6-GalCer 3a and activated cetuximab to initiate conjugation.

[0285] [Table 7]

[0286] The main problem posed in these experiments was to ensure the elimination of unreacted glycolipids in the medium after the coupling reaction with the antibody. Different methods were tried: Protein A, exclusion chromatography, electrophoresis, filtration. Success was achieved when the fractions obtained were washed three times by filtration on a VivaSpin15 column (MWCO: 50 Kda).

[0287] Two different experimental conditions were used to validate the purification process (see Table 7). - Fraction B: Cetuximab was not modified by TRAUT activation and 6-PEG3-NH2-GalCer 2a, which does not have the chemical ability to bind to Cetuximab, was added. This condition was used as a control to follow the clearance of unbound glycolipids under washing conditions. Given the high reactivity of 6-PEG3-NH2-GalCer 2a upon iNKT stimulation, the presence of even trace amounts of remaining derivatives would be detected by significant cytokine release; - Fraction A: Use of 6-Mal-PEG6-GalCer 3a and TRAUT-activated cetuximab to obtain the covalent linkage of glycolipids to antibodies and the targeted GalCer / cetuximab conjugate C1.

[0288] b) Purification and activation of iNKT by GalCer / cetuximab complexes Two series of experiments were performed, one with transfected CD1d Hela cells and one with non-CD1d Hela cells, evaluating three dilutions (10 μg / ml, 1 μg / ml and 0.1 μg / ml) of fractions A and B. In each series of Hela cells, the stimulatory activity of glycolipids alone was previously evaluated as a benchmark after IFN-γ secretion.

[0289] Starting concentration = The maximum theoretical concentration of free glycolipid (unbound) that may remain in the diluted fractions after the coupling reaction if the washing process is inefficient.

[0290] Observed concentration = The estimated theoretical concentration of glycolipid (based on reaction controls containing free glycolipid) that must remain in the diluted fractions following the wash process to induce the level of cytokine secretion observed.

[0291] Experiments show that the washing process results in the elimination of glycolipids (up to 99.9%).

[0292] Results with fraction B used as control: - As shown in Figure 14A, left panel, fractions obtained from a mixture of Cetuximab + 6-PEG3-NH2-GalCer 2a that cannot be bound after purification lead to a decrease in cytokine release after a 1 / 10 dilution. In this experiment using highly sensitive CD1d-Hela cells, the concentration of 6-PEG3-NH2-GalCer 2a remaining in the diluted fraction samples (observed concentration) seems to be at least 3 logs lower than the starting concentration added to the mixture (start concentration). At a dilution of 0.1 μg / ml, its activity becomes negligible, leading to a lack of iNKT stimulation. - The same experiment using non-CD1d HeLa cells (Figure 14B, left panel) leads to a lack of cytokine release even at 10 μg / ml. This suggests that in a physiological model, unbound 6-PEG3-NH2-GalCer 2a can be considered to have been completely removed from fraction B by the washing process, or at least to trace amounts (<10 in non-transfected HeLa cells). -10This indicates that the concentration can be considered as the detection limit (M detection limit).

[0293] Fraction A = Results with linked Cetuximab-GalCer conjugate C1: As shown, the complex GalCer / Cetuximab C1 formed after TRAUT activation of the antibody in the presence of 6-Mal-PEG6-GalCer 3a induces IFN-γ cytokine release by iNKT cells from all dilution fractions (10 μg / ml, 1 μg / ml and 0.1 μg / ml). These surprising results were observed from highly sensitive transfected CD1d cells as well as from non-CD1d cells (Figure 15C, left panel and 15D, left panel, respectively). A major interesting idea is that in both cases iNKT activation was maintained despite dilution of the fractions. These results seem to indicate activation of the CD1d pool that can be overexpressed in the presence of the cetuximab-GalCer complex C1.

[0294] It should be noted that the starting concentration is the maximum theoretical concentration estimated in the experiment, calculated in the case of failed washing and no clearance of glycolipid residues. However, previous experience showed that almost 99.9% of the excess (unbound) glycolipids is cleared after the first washing step. Therefore, the theoretical concentration estimated as a reference after three washing steps is consequently largely overestimated, and the "true" effect of the coupled cetuximab-GalCer conjugate is thereby in fact much more efficient.

[0295] This latter experiment, performed with non-CD1d tumor cells, shows that the coupled cetuximab-GalCer conjugate C1 is able to induce cytokine secretion at levels above the maximal release corresponding to that induced by 6-Mal-PEG3-GalCer 3a used in free form at the highest concentration.

[0296] These observations were confirmed by non-CD1d HEK293 cells and PBMC cells (peripheral blood mononuclear cells) (data not shown).

[0297] c) Mass spectrometry of GalCer / Cetuximab C1 To demonstrate that at least one or two molecules of 6-Mal-PEG6-GalCer 3a analog were linked to cetuximab, GalCer / cetuximab C1 was analyzed by mass spectrometry (ESI) (see Table 8 below).

[0298] [Table 8]

[0299] The full antibody spectrum showed several major peaks at 153191 Da and 155884 Da, and the deconvoluted spectrum of the peaks at 3.85 and 3.89 min LC corresponded to the heavy chain of cetuximab linked to GalCer fragments (data not shown). The methodology used for the analysis was destructive for the antibody (leading to unambiguous data only for binding at the heavy chain and unclear data for the degraded light chain), and the exact maximum number of linked GalCer residues in the whole antibody cannot yet be fully established.

[0300] (ii) Coupling and purification of glycolipids to cetuximab (compared to coupling in the absence of TRAUT) a) Coupling conditions For coupling to cetuximab the following conditions were maintained:

[0301] First, cetuximab was modified with TRAUT functional groups at a ratio of 100 TRAUT molecules per antibody, allowing the addition of at least four TRAUT functional groups to cetuximab as determined by a previously investigated Ellman reaction (data not shown). The mixture was washed and then incubated with ½ equivalent of 6-Mal-PEG6-GalCer 3a and activated cetuximab to initiate conjugation.

[0302] [Table 9]

[0303] The main problem posed in these experiments was to ensure the elimination of unreacted glycolipids in the medium after the coupling reaction with the antibody. Different methods were tried: Protein A, exclusion chromatography, electrophoresis, filtration. Success was achieved when the fraction obtained was washed three times by filtration on a VivaSpin15 column (MWCO: 50Kda) and then purified on a Superdex 200 10 / 300 GL column for size exclusion chromatography.

[0304] Two different experimental conditions were used to validate the purification process (see Table 9). - Fraction B: Cetuximab does not modify TRAUT activation and 6-Mal-PEG6-GalCer 3a. This condition was used as a control to follow the clearance of unbound glycolipids under washing conditions. Given the high reactivity of 6-Mal-PEG6-GalCer 3a upon iNKT stimulation, the presence of even trace amounts of remaining derivatives would be detected by significant cytokine release; - Fraction A: Use of 6-Mal-PEG6-GalCer 3a and TRAUT-activated cetuximab to obtain the covalent linkage of glycolipids to antibodies and the targeted GalCer / cetuximab conjugate C1.

[0305] b) Mass spectrometry of GalCer / cetuximab C1 To demonstrate that two molecules of 6-Mal-PEG6-GalCer 3a analog were linked to cetuximab, GalCer / cetuximab C1 was analyzed by mass spectrometry (ESI) (see Table 10 below).

[0306] [Table 10]

[0307] The full antibody spectrum showed several major peaks at 152 583 Da alone and 156 056 Da when coupled. This result indicates that on average two molecules of 6-Mal-PEG6-GalCer 3a (MW: 1 562 Da) were linked to the antibody. More detailed examination of the heavy and light chains indicates that coupling occurs primarily in the heavy chain.

[0308] c) Activation of iNKT by GalCer / cetuximab complexes Experiments were performed on non-CD1d-Hela cells and three dilutions of fractions A and B were evaluated (10 μg / ml, 1 μg / ml and 0.1 μg / ml). Mass spectrometry showed that two molecules of 6-Mal-PEG6-GalCer 3a were linked per antibody, so when 10 μg / ml of fraction A was used, this corresponds to 10 μg / ml of 6-Mal-PEG6-GalCer 3a. -7 In each series of HeLa cells, the stimulatory activity of glycolipids alone was previously evaluated as a baseline after IFN-γ secretion.

[0309] Results with fraction B used as a control: As shown in Figure 16, after purification, no cytokine secretion was observed in fractions from the mixture of cetuximab + 6-Mal-PEG6-GalCer 3a where no conjugation was observed by mass spectrometry, indicating that the washing process resulted in the elimination of unbound glycolipids.

[0310] Fraction A = Results with linked Cetuximab-GalCer conjugate C1: As shown, the complex GalCer / Cetuximab C1 formed after TRAUT activation of the antibody in the presence of 6-Mal-PEG6-GalCer 3a induces IFN-γ cytokine release by iNKT cells from all dilution fractions (10 μg / ml, 1 μg / ml and 0.1 μg / ml). These surprising results were observed with non-CD1d cells.

[0311] These results seem to indicate that the cetuximab-GalCer complex C1 is able to vectorize and release 6-Mal-PEG6-GalCer 3a into tumor cells, allowing its presentation with the weak CD1d expression observed in HeLa cells, resulting in the activation of iNKT cells.

[0312] (iv) Cetuximab in the GalCer / cetuximab complex can still recognize EGFR We then assessed whether cetuximab remained unchanged after coupling with 6-Mal-PEG6-Galcer 3a and was still able to recognize EGFR. As shown in Figure 13, cetuximab binding to cells expressing EGFR remained unchanged after coupling, as there was no difference between native cetuximab (straight from the bottle) and the three conditions tested for the coupling reaction. We confirmed the results with three different cell lines that also express EGFR (not shown).

[0313] (v) Cetuximab in GalCer / cetuximab complex and internalization After EGFR recognition, cetuximab is internalized, and in clinical situations, cetuximab reduces the surface expression of EGFR, reducing the ability of tumor cells to proliferate uncontrollably. The internalization of GalCer / cetuximab complex C1 was followed by live microscopy for 21 hours. Complex C1 was labeled with a marker that only glows red when it is internalized in acidic endosomes / lysosomes. Most of the HeLa cells were shown to have internalized complex C1 from 11 hours of co-incubation (data not shown). We hypothesized that after internalization and support in lysosomes, the C1 complex releases 6-Mal-PEG6-GalCer 3a under acidic conditions, allowing it to be loaded onto CD1d molecules and presented on the surface of tumor cells, resulting in the iNKT cell activation observed in part iii) above.

[0314] (vi) ADCC behavior of GalCer / cetuximab conjugates Another important feature of cetuximab is its ability to induce ADCC. It was important to check the conservation of its behavior from GalCer / cetuximab complex C1. ADCC assays were performed on HeLa and HCT116 cell lines (Figure 14A and B, respectively), because the latter turned out to be the most responsive cell line among several cell lines we tested in preliminary experiments, and HCT116 presents a Kras mutation. Target cells (HCT116 and HeLa cells) were co-incubated with cetuximab alone (left panel, blue) or with cetuximab-GalCer complex C1 (right panel, red) for 1 h. ADCC was then initiated by the addition of NK92-CD16+ cells (cell line routinely used for ADCC assays), followed by incubation for 24 h. The mortality of target cells was analyzed by flow cytometry.

[0315] The ADCC potency of cetuximab was preserved across all conditions in both models, indicating that conjugation of the glycolipid fragment does not alter the behavior of the antibody with respect to EGFR recognition.

[0316] (vii) Conclusion The covalently linked GalCer / cetuximab conjugate C1 can use CD1d-tumor cells as antigen-presenting partners to activate hiNKT cells and release cytokines. The important information is that cancer cells previously considered CD1d-negative can act as self-presenting cells through a previously undetected extremely low CD1d pool, and this behavior is related to the extraordinary potency of the cetuximab-GalCer conjugate C1. Moreover, despite the linkage to the antibody via a relatively short PEG spacer, the GalCer derivative is still active.

[0317] One hypothesis that can be considered for our data is that cetuximab achieves concentration of glycolipids in EGFR-tumor cells through vectorization and possibly internalization process of cetuximab-GalCer complex C1. Subsequent release of glycolipids from the complex may then possibly occur under acidic intracellular conditions or antibody degradation, allowing loading of unknown internal pools of CD1d that may be expressed on the surface of tumor cell membranes. It seems that this CD1d turnover can recruit iNKT cells, induce cytokine stimulation, and restore immune response near the tumor environment.

[0318] In this sense, the cetuximab-GalCer conjugate C1 can be considered as a powerful drug candidate for immunotherapy, providing the ADCC properties of cetuximab or at least its cytotoxic effect, as well as enhanced cytotoxic effect combined with strong immune stimulatory activity from iNKT.

[0319] conclusion The present application discloses a novel potent immunostimulator, 6-PEG3-NH2-GalCer 2a, which expresses hiNKT stimulatory capacity approximately 1000-fold higher than that of the parent KRN7000.

[0320] More interestingly, the corresponding GalCer / cetuximab conjugate C1 (see FIG. 15) retains the ability to activate iNKT cells and induce cytokine release.

[0321] These data may lead to a redefinition of the concept of CD1d-negative cells, since some tumor cells (HeLa and HEK293) previously considered to be CD1d-negative constitutively express CD1d at levels sufficient to effectively activate iNKT cells, albeit at nearly undetectable levels. iNKT cells, which themselves have low levels at experimental physiological levels, induce cytokine release when loaded with 6-PEG3-NH2-GalCer glycolipid 2a, but also when loaded with GalCer / cetuximab conjugate C1. This suggests that antibodies can already be considered as excellent vehicles to carry GalCer immunostimulants within the tumor environment to initiate iNKT stimulation. This process can circumvent the need for classical CD1d-presenting cells (such as monocytes, macrophages or dendritic cells), and cancer cells can self-present even when glycolipid agonists are linked to antibodies.

Claims

1. A compound of formula (II): 【Chemistry 1】 [wherein X is a PEG fragment -[CH 2 -CH 2 -O] m (m is an integer from 1 to 24), an alkyl chain -(CH 2 ) n - (where n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONHR1, -COOR1, -CSR1, -CSNHR1 or -CSOR1; R1 is an alkyl group, an aryl group, a heterocyclic group, a PEG fragment -[CH 2 -CH 2 -O] p -R2 (p is an integer from 1 to 24), or an alkyl chain -(CH 2 ) q -R2 (q is an integer from 1 to 24), R2 represents a functional reactive group that allows coupling to a carrier D, or represents LD, where L is a linker and D is a carrier, and the functional reactive group that allows coupling to the carrier D is N-maleimide, N3, alkyne, alkene, acryloyl, norbornene, cyclooctadiene, TCO, tetrazine, isocyanate, thiol or aldehyde. An iNKT activator consisting of

2. a compound of formula (V): 【Chemistry 2】 a compound of formula (VI): 【Chemistry 3】 a compound of formula (VII): 【Chemistry 4】 and a compound of formula (VIII): 【Chemistry 5】 The iNKT activator of claim 1, selected from the group consisting of:

3. A conjugate comprising at least one iNKT activator coupled to at least one carrier, The conjugate is (i) A compound of formula (II) 【Chemistry 6】 [wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), an alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONHR1, -COOR1, -CSR1, -CSNHR1 or -CSOR1, R1 being a PEG fragment -[CH 2 -CH 2 -O] p -LD (p is an integer from 1 to 24), or an alkyl chain -(CH 2 ) q -L-D, where q is an integer from 1 to 24, where L is a linker and D is a carrier; or (ii) at least one iNKT activator of formula (II) above, wherein X is a PEG fragment -[CH2-CH2-O] m (m is an integer from 1 to 24), an alkyl chain -(CH2) n - (n is an integer from 1 to 24), or a branched hydrocarbon group, R represents -CO-R1, -CONHR1, -COOR1, -CSR1, -CSNHR1 or -CSOR1, and R1 is a PEG fragment -[CH2-CH2-O] p -R2 (where p is an integer from 1 to 24), or an alkyl chain -(CH2) q -R2 (q is an integer from 1 to 24), R2 being a functional reactive group that allows coupling to said carrier D, said functional reactive group being N-maleimide, N3, alkyne, alkene, acryloyl, norbornene, cyclooctadiene, TCO, tetrazine, isocyanate, thiol or aldehyde] to one carrier D, Conjugate.

4. The iNKT activator of claim 1 or the conjugate of claim 3, wherein carrier D is a therapeutic agent and / or a targeting agent.

5. The iNKT activator of claim 1 or 4 or the conjugate of claim 3 or 4, wherein the carrier D is an antibody, an antibody fragment, a sugar, a lectin, an affinin, a growth factor, an antigen, a protein, a peptide, a glycoprotein, an aptamer, a virus and / or a carbohydrate.

6. A vector comprising at least one iNKT activator according to any one of claims 1, 2, 4 or 5, and / or at least one conjugate according to any one of claims 3 to 5.

7. The vector of claim 6, which is a nanoparticle.

8. (i) at least one iNKT activator according to any one of claims 1, 2, 4 and 5, at least one conjugate according to any one of claims 3 to 5, and / or at least one vector according to claim 6 or 7; (ii) at least one pharma- ceutically acceptable vehicle; 23. A pharmaceutical composition comprising:

9. Use of an iNKT activator described in any one of claims 1, 2, 4 and 5, a conjugate described in any one of claims 3 to 5, a vector described in claim 6 or 7, or a pharmaceutical composition described in claim 8 in the manufacture of a medicament.

10. 10. Use according to claim 9 for the prevention and / or treatment of cancer, an autoimmune disease, an inflammatory disease, a viral infection, a bacterial infection and / or a parasitic disease.

11. 8. In vitro use of an iNKT activator according to any one of claims 1, 2, 4 or 5, a conjugate according to any one of claims 3 to 5, or a vector according to claim 6 or 7 for activating iNKT cells.

12. 9. The pharmaceutical composition according to claim 8 for treating a disease requiring stimulation of an immune response.

13. 13. The pharmaceutical composition according to claim 12, wherein the disease requiring stimulation of an immune response is cancer, an autoimmune disease, an inflammatory disease, a viral infection, a bacterial infection and / or a parasitic disease.

Citation Information

Patent Citations

  • Charles m

    US1985A

  • Quantitative microarray of intact glycolipid CD1d interaction and correlation with cell-based cytokine production

    US20090275483A1

  • New carbamate glycolipid and use thereof

    WO2013162016A1

  • Galactopyranosyl derivatives useful as medicaments

    WO2014001204A1